Roivant director settles taxes with 1,743 shares

Roivant Sciences Ltd. (ROIV) director Meghan Fitzgerald had 1,743 Common Shares withheld on September 10, 2026 as a net settlement to satisfy tax withholding obligations tied to vesting of previously granted director equity awards.

Rhea-AI Filing Summary

Roivant Sciences Ltd. (ROIV) director Meghan Fitzgerald had 1,743 Common Shares withheld on September 10, 2026 as a net settlement to satisfy tax withholding obligations tied to vesting of previously granted director equity awards. The shares were valued at $40.94 per share, leaving her with 41,220 Common Shares held directly after this transaction. No Rule 10b5-1 trading plan is reported for this disposition.

Insider Trade Summary

Tax Withholding: 1,743 shares

Tax Withholding 1 txn

Insider Fitzgerald Meghan

Role Director

Type	Security	Shares	Price	Value
Tax Withholding	Common Shares F1	1,743	$40.94	$71K

Holdings After Transaction: Common Shares — 41,220 shares (Direct)

Footnotes (1)

1. F1. Represents the "net settlement" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares.

Key Figures

Shares withheld for taxes: 1,743 shares Per-share value: $40.94 per share Shares held after transaction: 41,220 shares

3 metrics

Shares withheld for taxes 1,743 shares Net settlement for tax withholding on vested Common Shares on September 10, 2026

Per-share value $40.94 per share Valuation applied to the 1,743 withheld Common Shares

Shares held after transaction 41,220 shares Directly owned Common Shares by Meghan Fitzgerald after the withholding

Key Terms

net settlement, Non-Employee Director Compensation Plan, tax withholding obligations

3 terms

net settlement financial

"Represents the "net settlement" by the Issuer of Common Shares"

Non-Employee Director Compensation Plan financial

"previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan"

tax withholding obligations financial

"to satisfy applicable tax withholding obligations in connection with the vesting"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What transaction did Roivant Sciences (ROIV) director Meghan Fitzgerald report?

She reported a withholding of 1,743 Common Shares on September 10, 2026, used as a net settlement to cover tax withholding obligations arising from the vesting and settlement of previously granted director shares.

At what price were the withheld ROIV shares valued in this Form 4?

The 1,743 withheld Common Shares were valued at $40.94 per share, according to the Form 4. This valuation was used in connection with satisfying applicable tax withholding obligations on the vesting equity award.

How many Roivant Sciences (ROIV) shares does Meghan Fitzgerald hold after this transaction?

Following the September 10, 2026 withholding transaction, Meghan Fitzgerald directly holds 41,220 Common Shares of Roivant Sciences Ltd., as reported in the Form 4.

Was the Meghan Fitzgerald ROIV Form 4 transaction a market sale?

No. The Form 4 describes the transaction as a payment of tax liability by delivering or withholding securities, characterized in the footnote as a net settlement of shares upon vesting, not an open-market sale.

Is the Meghan Fitzgerald ROIV Form 4 transaction under a Rule 10b5-1 plan?

No. The Form 4 indicates that no Rule 10b5-1 trading plan is affirmed for this transaction; it reflects a net-share withholding to cover taxes on vested director equity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/14/2026 - 06:29 PM Accepted by SEC EDGAR 09/14/2026 - 06:29 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fitzgerald Meghan

(Last) (First) (Middle)

C/O ROIVANT SCIENCES LTD.

7TH FLOOR, 50 BROADWAY

(Street)

LONDON SW1H 0DB

(City) (State) (Zip)

UNITED KINGDOM

(Country)

2. Issuer Name and Ticker or Trading Symbol
Roivant Sciences Ltd. [ ROIV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	09/10/2026		F		1,743(1)	D	$40.94	41,220	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the "net settlement" by the Issuer of Common Shares previously granted to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Plan in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such Common Shares.

Remarks:

	By: /s/ Sam Kaplan, as Attorney-in-Fact for Meghan FitzGerald	09/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)